Cidara Therapeutics to Present Clinical Phase 2b Data and Preclinical H5N1 Data on CD388 at ISRV’s 8th AVG and 3rd IMRP 2025 Meeting
Cidara Therapeutics (Nasdaq: CDTX) announced two upcoming oral presentations at the International Society for Respiratory Viruses (ISRV) conference in Singapore, September 17-20, 2025. The presentations will feature clinical and preclinical data for their drug candidate CD388.
The first presentation is a late-breaking abstract showcasing Phase 2b clinical trial results (NAVIGATE study) evaluating CD388's efficacy and safety for influenza prevention in healthy adults. The second presentation will discuss preclinical data demonstrating CD388's protective effects against H5N1 influenza virus in ferret models.
Cidara Therapeutics (Nasdaq: CDTX) ha annunciato due presentazioni orali al congresso della International Society for Respiratory Viruses (ISRV) a Singapore, dal 17 al 20 settembre 2025. Le comunicazioni includeranno dati clinici e preclinici sul loro candidato farmaco CD388.
La prima presentazione, classificata come late-breaking, mostrerà i risultati del trial clinico di fase 2b (studio NAVIGATE) che valuta efficacia e sicurezza di CD388 nella prevenzione dell’influenza in adulti sani. La seconda illustrerà dati preclinici che evidenziano gli effetti protettivi di CD388 contro il virus dell’influenza H5N1 in modelli di furetto.
Cidara Therapeutics (Nasdaq: CDTX) anunció dos presentaciones orales en la conferencia de la International Society for Respiratory Viruses (ISRV) en Singapur, del 17 al 20 de septiembre de 2025. Las presentaciones incluirán datos clínicos y preclínicos sobre su candidato farmacológico CD388.
La primera comunicación, de última hora (late-breaking), mostrará los resultados del ensayo clínico de fase 2b (estudio NAVIGATE) que evalúa la eficacia y seguridad de CD388 para la prevención de la gripe en adultos sanos. La segunda tratará datos preclínicos que demuestran los efectos protectores de CD388 frente al virus de la gripe H5N1 en modelos de hurón.
Cidara Therapeutics (Nasdaq: CDTX)는 2025년 9월 17일부터 20일까지 싱가포르에서 열리는 국제호흡기바이러스학회(ISRV)에서 두 건의 구두 발표를 할 예정이라고 발표했습니다. 발표에서는 후보 약물 CD388에 대한 임상 및 비임상 데이터가 소개됩니다.
첫 번째 발표는 라이트 브레이킹(late-breaking) 초록으로, 성인 건강인을 대상으로 한 인플루엔자 예방 효과와 안전성을 평가한 2상b 임상시험(NAVIGATE 연구) 결과를 공개합니다. 두 번째 발표는 퍼렛(족제비류) 모델에서의 H5N1 인플루엔자 바이러스에 대한 CD388의 보호 효과를 다루는 비임상 데이터를 설명합니다.
Cidara Therapeutics (Nasdaq: CDTX) a annoncé deux présentations orales lors de la conférence de l'International Society for Respiratory Viruses (ISRV) à Singapour, du 17 au 20 septembre 2025. Les présentations porteront sur des données cliniques et précliniques concernant leur candidat-médicament CD388.
La première, un abstract « late-breaking », présentera les résultats de l'essai clinique de phase 2b (étude NAVIGATE) évaluant l'efficacité et la sécurité de CD388 pour la prévention de la grippe chez des adultes en bonne santé. La seconde exposera des données précliniques montrant les effets protecteurs de CD388 contre le virus de la grippe H5N1 dans des modèles de furet.
Cidara Therapeutics (Nasdaq: CDTX) gab zwei anstehende mündliche Präsentationen auf der Konferenz der International Society for Respiratory Viruses (ISRV) in Singapur bekannt, die vom 17. bis 20. September 2025 stattfindet. Gezeigt werden klinische und präklinische Daten zu ihrem Wirkstoffkandidaten CD388.
Die erste Präsentation ist ein Late-Breaking-Abstract und präsentiert die Ergebnisse der Phase-2b-Studie (NAVIGATE), die Wirksamkeit und Sicherheit von CD388 zur Grippeprävention bei gesunden Erwachsenen bewertet. Die zweite Präsentation stellt präklinische Daten vor, die die schützenden Effekte von CD388 gegen das H5N1-Influenzavirus in Frettchenmodellen zeigen.
- None.
- None.
SAN DIEGO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced it will have two oral presentations, one of which is late-breaking, during the International Society for Respiratory Viruses (ISRV) 8th AntiViral Group (AVG) Meeting and 3rd International Meeting on Respiratory Pathogens (IMRP). The conference is taking place September 17-20, 2025, in Singapore.
Presentation details are summarized below:
Late-Breaking Abstract Title: NAVIGATE: A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multicenter Dose-ranging Trial to Evaluate the Efficacy and Safety of CD388 for Prevention of Influenza Illness in Healthy Adults
Presenter: Rick Bright, Ph.D. Bright Global Health, Cidara Therapeutics
Session: AVG Session 3
Session Date and Time: Wednesday, September 17, 2025, 3:50 – 4:05 p.m. SGT
Abstract Title: A Single Prophylactic dose of CD388 Provides Protection Against Highly Pathogenic Bovine-Origin Influenza A (H5N1) Virus in the Ferret Model
Presenter: Andreev Konstantin, Ph.D. St. Jude Children’s Research Hospital
Session: Parallel Session 2 (Track 1)
Session Date and Time: Friday, September 19, 2025, 10:30 a.m. – 12:30 p.m. SGT
About Cidara Therapeutics
Cidara Therapeutics is using its proprietary Cloudbreak® platform to develop novel DFCs comprising targeted small molecules or peptides coupled to a proprietary human antibody fragment. Cidara’s lead DFC candidate, CD388, is a long-acting antiviral designed to achieve universal prevention of seasonal and pandemic influenza with a single dose by directly inhibiting viral proliferation. In June 2023, CD388 was granted Fast Track Designation by the FDA. Cidara announced positive top-line results from its Phase 2b NAVIGATE trial in June 2025. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.
INVESTOR CONTACT:
Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com
MEDIA CONTACT:
Michael Fitzhugh
LifeSci Communications
(628) 234-3889
mfitzhugh@lifescicomms.com
FAQ
When will Cidara Therapeutics (CDTX) present their Phase 2b CD388 clinical trial results?
What is the purpose of Cidara Therapeutics' CD388 Phase 2b NAVIGATE trial?
What preclinical data will CDTX present about CD388?
What is Cidara Therapeutics' technology platform?
